MEDICA2025 Concludes Successfully!

On November 20, 2025, the 57th International Medical and Medical Devices Exhibition (MEDICA 2025) concluded successfully in Düsseldorf, Germany. Breaking through with a full industrial chain and standing out with core strength! Danda Bio made a stunning appearance with its "raw materials - instruments" integrated technology matrix. It not only demonstrated the cutting-edge strength of Chinese biotechnology to the world, but also gained high recognition from international customers with professional product capabilities and continuous innovation, adding a new engine to its global layout.

DIAGREAT builds a full-chain IVD comprehensive solution, covering the supply of core reagent raw materials, comprehensive reagent solutions, and the construction of high-precision testing instrument platforms, achieving end-to-end coverage and independent control. Relying on the continuous iteration and breakthrough of core technologies, DIAGREAT has launched a fully automated chemiluminescence solution for therapeutic drug monitoring (TDM), while establishing a comprehensive system of "fully automated preprocessing + drug monitoring reagents + result interpretation services". It efficiently realizes full-process intelligence, eliminates tedious operational steps, and truly makes drug concentration monitoring faster, more accurate, and simpler, providing strong support for precision medicine.

DIAGREAT has always taken R&D and innovation as the engine to drive enterprise advancement. Boasting a core R&D team of top-tier talents, it injects sustained momentum into technological breakthroughs. Currently, its core products have successfully obtained the EU CE certification, as well as rigorous market access certifications from multiple countries including Italy, Mexico, Venezuela, and Ecuador. These achievements not only serve as authoritative proof of the company's professionalism in medical technology but also highlight Danda Bio's technological leadership in the global market. In its global layout, DIAGREAT has established a marketing network covering more than 60 countries and regions, laying a solid foundation for business expansion. Consequently, its products have gained in-depth recognition and industry acclaim worldwide.

In the future, DIAGREAT will continue to deepen its footprint in precision medicine, driven by technological innovation, and constantly iterate and optimize its product and service systems. Meanwhile, we will fully promote the innovation of therapeutic drug monitoring (TDM) technology, facilitate the upgrading of clinical precision medicine standards, and fulfill the responsibilities of a local enterprise. We firmly believe that with the joint efforts of outstanding national enterprises like DIAGREAT, China's IVD industry will keep reaching new heights, providing global customers with more high-quality and efficient medical solutions to empower the development of human health.